ClinicalTrials.Veeva

Menu
O

Ophthalmic Consultants of Boston | Boston, MA

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Ranibizumab
Dexamethasone Phosphate
Encorafenib
Binimetinib
Lampalizumab
Bromfenac
APL-2
KSI-301
Aflibercept
NT-501

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

29 of 136 total trials
Locations recently updated

A Clinical Trial Evaluating the Safety and Efficacy of a Single Subretinal Injection of AGTC-501 in Participants With XLRP

This study will evaluate and compare the safety, efficacy, and tolerability of 2 doses of a recombinant adeno-associated virus vector (AGTC-501) to a...

Enrolling
X-Linked Retinitis Pigmentosa
Drug: Control
Biological: rAAV2tYF-GRK1-hRPGRco

The purpose of this study is to learn about the effects of three study medicines (encorafenib, binimetinib, and pembrolizumab) given together for the...

Active, not recruiting
Melanoma
Drug: Binimetinib
Drug: Encorafenib

Investigate the Safety, Pharmacokinetics, and Treatment effects of Single and Multi-dose of Intravitreal AVD-104 in participants with geographic atro...

Active, not recruiting
Macular Degeneration
Geographic Atrophy of the Macula
Drug: AVD-104
Drug: Avacincaptad
Locations recently updated

The primary objective is to determine the safety and efficacy of belzupacap sarotalocan (bel-sar) compared to sham control in patients with primary i...

Enrolling
Indeterminate Lesions
Ocular Melanoma
Device: Suprachoroidal Microinjector
Drug: Bel-sar

The primary purpose of the study is to determine if IVT injections of ANX007 every month reduce vision loss in participants with GA secondary to age-...

Enrolling
Geographic Atrophy
Drug: ANX007
Other: Sham Administration

A phase 3 study to demonstrate whether lorlatinib given as monotherapy is superior to crizotinib alone in prolonging the progression-free survival in...

Active, not recruiting
Carcinoma, Non-Small-Cell Lung
Drug: Crizotinib
Drug: Lorlatinib

Age-related macular degeneration (AMD) is an eye disease which causes people to lose their sharp central vision over time. Aging damages the macula,...

Enrolling
Age-Related Macular Degeneration
Drug: Acyclovir
Drug: trimethoprim-sulfamethoxazole

This study will evaluate the efficacy, safety, and pharmacokinetics of the PDS with Ranibizumab in participants with DME when treated every 24 weeks...

Active, not recruiting
Diabetic Macular Edema
Drug: PDS Implant Pre-Filled with 100 mg/mL Ranibizumab
Drug: Ranibizumab refill exchange

The purpose of this study is to evaluate change in geographic atrophy (GA) lesion growth of eyes treated with JNJ-81201887 compared to sham control.

Active, not recruiting
Geographic Atrophy
Drug: Triamcinolone
Other: Sham Procedure

The purpose of this study is to assess the efficacy, safety, pharmacokinetics, and pharmacodynamics of subcutaneous (SC) satralizumab, a recombinant,...

Enrolling
TED
Thyroid Eye Disease
Drug: Satralizumab
Drug: Placebo

This study is open to people 50 years or older with an eye condition called geographic atrophy. The purpose of this study is to compare a medicine ca...

Begins enrollment this month
Macular Degeneration, Age-related
Geographic Atrophy
Drug: Pegcetacoplan
Drug: Sham comparator to BI 771716

This is a multicenter, open-label, dose escalation (Cohort 1) to masked, randomized, parallel-groups (Cohort 2) and (Cohort 3) study to evaluate the...

Enrolling
Open-angle Glaucoma
Ocular Hypertension
Other: Sham Administration
Drug: AGN-193408 SR

This is a clinical trial assessing the efficacy, safety, and tolerability of an investigational drug, veligrotug (VRDN-001), in participants with chr...

Active, not recruiting
Thyroid Eye Disease
Drug: Veligrotug (VRDN-001)
Drug: Placebo

This is a phase 3, open-label, multicenter, extension study to evaluate the long-term safety and efficacy of pegcetacoplan (APL-2) in subjects with g...

Active, not recruiting
Geographic Atrophy Secondary to Age-related Macular Degeneration
Drug: PEGCETACOPLAN (APL-2)

This is an open-label, multicenter, non-randomized, Phase 2 study to determine the safety, tolerability and efficacy of encorafenib given in combinat...

Active, not recruiting
Non-small Cell Lung Cancer
Drug: encorafenib
Drug: binimetinib

The purpose of this study is to assess long-term safety of avacincaptad pegol intravitreal administration for patients with geographic atrophy (GA) w...

Active, not recruiting
Age-Related Macular Degeneration
Geographic Atrophy
Drug: avacincaptad pegol

This study evaluates the duration of intraocular pressure (IOP)-lowering effect and safety of as needed administrations of Bimatoprost sustained rele...

Active, not recruiting
Open-Angle Glaucoma
Ocular Hypertension
Drug: Bimatoprost (SR)

This study will evaluate the long-term safety and tolerability of the Port Delivery System with ranibizumab (PDS) (100 mg/mL) in participants with ne...

Enrolling
Neovascular Age-Related Macular Degeneration
Drug: PDS Implant with Ranibizumab 100 mg/mL

This is a prospective, observational study designed to evaluate the long-term safety and efficacy of RGX-314. Eligible participants are those who wer...

Invitation-only
Wet Macular Degeneration
Neovascular Age-related Macular Degeneration
Genetic: RGX-314

The purpose of this study is to evaluate the long-term safety of GT005 in participants with Geographic Atrophy (GA) secondary to AMD who have been tr...

Invitation-only
Age Related Macular Degeneration (AMD)
Genetic: GT005

Trial sponsors

Pfizer logo
Roche logo
AbbVie logo
Jaeb Center for Health Research logo
E
A
N
Aldeyra Therapeutics logo
C
Janssen (J&J Innovative Medicine) logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems